The growing presence of cardiovascular diseases coexisting with other diseases in the population, and the increasing number of deaths associated with it causes that so-called fixed-dose combination (FDC) preparations are being developed to be used in polytherapy.

In recent years, a number of studies have been conducted to assess the effectiveness of this type of combination in therapy and to prevent incidents associated with cardiovascular diseases. Many studies of this type also included studies aiming at the evaluation of the effectiveness of the concomitant use of rosuvastatin, candesartan, and hydrochlorothiazide in patients with specific cardiovascular disorders (1). The chemical structures of the tested substances are shown in Figure 1.

Candesartan (CAN) – 2-Ethoxy-1-[(2’-[(1H-tetrazol-5-yl)-4-biphenyl]methyl]-1H-benzimidazole-7-carboxylic acid (Fig. 1A) is a selective AT1 receptor antagonist for angiotensin II. Blocking these receptors leads to a lowering of blood pressure, which is why these drugs are used to treat hypertension.

Rosuvastatin (ROS) – (3R,5S,6E)-7-{4-(4-Fluorophenyl)-6-isopropyl-2-[methyl (methylsulfonyl)amino]-5-pyrimidinyl}-3,5-dihydroxy-6-heptenoic acid (Fig. 1B) belongs to the group of drugs blocking the enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), which is crucial for cholesterol synthesis. As a result, both LDL and total cholesterol are lowered. In addition to lowering cholesterol, statins have pleiotropic effects such as regulation of nitric oxide synthesis leading to vasodilatation and show an antioxidant effect.

Hydrochlorothiazide (HCT) – 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide (Fig. 1C) is a drug with diuretic and
hypotensive effect from the thiazide group. It works by inhibiting the reverse transport of sodium ions. In this way, it increases the excretion of sodium and water from the body. Its special significance results from the long duration of action and is used in the long-term treatment of hypertension and chronic heart failure. In addition, hydrochlorothiazide has been used in the treatment of acute and chronic edema.

A number of methods have been described in the literature that can be used to quantify the compounds mentioned. The most commonly used methods are separation methods. The results of simultaneous determination of CAN and HCT using the HPLC method are presented, among others, in papers (2-5), by TLC method in papers (6-8).

In addition to separation methods, a spectrophotometric method using curves derived from absorption spectra was successfully used to determine active substances in two-component mixtures (10-12). ROS was also determined using separation methods such as HPLC (13-15), TLC (16, 17), spectrophotometric method (18, 19), and electroanalytical methods (20-24).

The results of studies aiming at the evaluation of the effectiveness of simultaneous use of the above-mentioned drugs indicate a beneficial effect of polytherapy (rosuvastatin 10 mg daily, candesartan 16 mg daily, and hydrochlorothiazide 12.5 mg daily), which is associated with a significantly lower rate of cardiovascular events than in the placebo group (25). Possible interactions between rosuvastatin and candesartan and their tolerance by patients were also investigated. The results confirmed that the pharmacokinetic properties met the criteria for bioequivalence. It was found that the FDC preparations were safe, well-tolerated and no significant differences in the assessment of treatment safety were observed (26). Therefore, the authors decided to develop a method for the simultaneous determination of candesartan, hydrochlorothiazide, and rosuvastatin as active ingredients of a potential FDC (fixed-dose combination) preparations using thin-layer chromatography with densitometric detection.

**EXPERIMENTAL**

**Instruments and materials**

TLC system consists of Camag Linomat autosampler (Sonnenmattstrasse 11, CH-4132 Muttenz, Switzerland), Camag microsyringe (100 µL), and Camag TLC scanner 35/N/30319 with winCATS software. A short wavelength UV lamp emitting at 254 nm and 366 nm was also used (Desaga, Wiesloch, Germany). Aluminum-backed TLC silica gel 60 F_{254} plates (20 × 20 cm) with 0.25 mm thickness were obtained from E. Merck, Darmstadt, Germany.

**Chemicals**

Reference standards: candesartan (CAN) – 2-ethoxy-1-{(4-[2H-1,2,3,4-tetrazol-5-yl]phenylphenyl)methyl}-1H-1,3-benzodiazole-7-carboxylic acid, CAS Number: 145040-37-5, hydrochlorothiazide (HCT) – 6-chloro-1,1-dioxo-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide, CAS Number: 58-93-5, rosuvastatin (ROS) – (3R,5S,6E)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5 dihydroxyhept-6-enolic acid, CAS Number: 147098-20-2, were supplied by Sigma-Aldrich (Germany). Hexane, ethyl acetate, methanol, 95.5% acetic acid were purchased from Merck (Germany).

Figure 1. Chemical structure of candesartan (A), rosuvastatin (B), and hydrochlorothiazide (C).
All reagents and solvents used were of analytical reagent grade.

**Pharmaceutical preparations**

Two pharmaceutical preparations were used for the determinations: Carzap® HCT 16 mg + 12.5 mg manufactured by Zentiva, Prague, Czech Republic, series No. 1608A045, one tablet contains 16 mg of candesartan cilexetil and 12.5 mg hydrochlorothiazide; Suvardio 10 mg manufactured by Sandoz GmbH, Kundl, Austria, series No. GB1246 one tablet contains 10 mg of rosuvastatin calcium.

**Standard solutions**

The standard solutions were prepared by weighing the appropriate mass of the standard substance on an analytical balance, transferring it quantitatively into a 10 mL volumetric flask, and making it up to the given volume with methanol. By following this procedure for all tested substances, clear solutions were obtained at the following concentrations: CAN: 0.960 mg/mL and 0.048 mg/mL, HCT: 0.760 mg/mL and 0.058 mg/mL, ROS: 0.640 mg/mL and 0.032 mg/mL.

**Model mixture**

10 tablets of Carzap® HCT and 10 tablets of Suvardio were powdered. From the powdered tablet mass, sample weights corresponding to the average tablet weight of the tested preparations were made and mixed. The model mixture was extracted with 5 mL of methanol by placing the extract in an ultrasonic bath for 15 min. The solution was filtered through EMD Millipore Syringe Filters 0.45 µm. The mixture was diluted four times before the determination. The prepared solution containing CAN: 41.6%, HCT: 32.5%, ROS: 26.0% corresponded in terms of composition and content to the mixture used in polytherapy in clinical studies conducted and described by Yusuf et al (25).

**Mobile phase:**

Hexane – ethyl acetate – methanol – water – 95.5% acetic acid (8.4 : 8 : 3 : 0.4 : 0.2 V/V)

**Chromatographic conditions**

In order to determine the separation conditions of analyzed components, 2 µl of appropriate standard solutions of CAN at a concentration of 0.960 mg/mL, HCT at a concentration of 0.760 mg/mL, ROS at a concentration of 0.640 mg/mL, and the model mixture solution were applied in the form of 8 mm bands to the chromatographic plates measuring 10 × 10 cm with silica gel G F254. Chromatograms were developed using a mobile phase composed of: hexane – ethyl acetate – methanol – water – 95.5% acetic acid (8.4 : 8 : 3 : 0.4 : 0.2 V/V). The chromatogram was developed to a height of 95 mm in a chromatographic chamber saturated with the mobile phase for 15 min. After development, the chromatograms were dried at room temperature and subjected to visual analysis illuminating the chromatographic plate with monochromatic light at a wavelength of l = 254 nm, and then the densitometric measurements were also performed.

**METHOD VALIDATION**

The method was validated according to the ICH recommendations (27) and Polish Pharmacopoeia, XIth edition (28).

**Specificity**

Specificity was checked by comparing the retention factor (Rf) for the peaks of the standard solutions and model mixture. The resolution of the registered peaks was calculated (a – separation factor, Rs – resolution factor).

**Accuracy**

The accuracy of the method was determined by providing the percentage of recovery (% R) of the tested components. For this purpose, standard substances in amounts from 80% to 120% of the determined content were added to the model mixture. The analysis was carried out before and after the addition of standard substances. The recovery percentage was calculated according to the formula: R = A/B × 100%, where: A – the determined amount of tested substance, B – the known amount of tested substance. Five repetitions were performed for each level.

**Precision**

Compliance of the determination results was checked on standard solutions prepared by dissolving the ingredients in methanol, taking into account the proportions in which they most often occur in polytherapy. Five determinations were carried out at three concentration levels: 50%, 100%, and 150% of the determined content.

**Linearity**

Linearity was defined as the relationship between peak areas (p) and concentration (µg/spot), using solutions at the following concentrations: CAN 0.048 mg/spot, HCT 0.058 mg/spot, ROS 0.032 mg/spot. Two measurements were made for
each component for concentrations respectively: 0.048, 0.240, 0.432, 0.672, 0.864, 1.056, 1.248, 1.440, 1.632, 1.824 mg/spot for CAN, from 0.058, 0.174, 0.290, 0.406, 0522, 0.638, 0.754, 0.870, 0.986, 1.000, 1.102 mg/spot for HCT and from 0.032, 0.160, 0.288, 0.448, 0.576, 0.704, 0.832, 0.960, 1.088, 1.216 mg/spot for ROS.

Limit of detection (LOD) and limit of quantification (LOQ)

The limit of detection and quantification was determined from the linearity in the concentration ranges: from 0.048 to 0.0864 mg/spot for CAN, from 0.058 to 0.522 mg/spot for HCT and from 0.032 to 0.832 mg/spot for ROS. The following formulas
were used in the calculations: $LOD = 3.3 \times S_y / A$, $LOQ = 10 \times S_y / A$, in which: $S_y$ – standard error of the estimate, $A$ – the slope of the straight line.

**Robustness**

The robustness of the method was verified by analyzing the influence of slight changes in the system on the obtained results. The following parameters were changed: chromatographic chamber saturation time ± 10 min, the volume of the mobile phase ± 5%, type of the stationary phase (HPTLC 60F254), type of the chromatographic chamber used. None of these changes influenced the obtained results, which may prove that the method is resistant.

---

**Table 1. Validation of the developed method with the statistical evaluation.**

| Parameters                  | CAN         | HCT        | ROS         |
|-----------------------------|-------------|------------|-------------|
| $R_f$                       | ~ 0.66      | ~ 0.41     | ~ 0.53      |
| Linearity range (µg/spot)   | 0.048 - 1.824 | 0.058 - 1.102 | 0.032 - 1.216 |
| LOD (µg/spot)               | 0.056       | 0.043      | 0.049       |
| $a$                         | 5828.7      | 6992.3     | 5051.0      |
| $S_y$                       | 98.6        | 91.3       | 75.8        |
| LOQ (µg/spot)               | 0.169       | 0.130      | 0.150       |
| Precision 50% [mg/mL]       |             |            |             |
| $X$                         | 0.558       | 0.254      | 0.316       |
| $SD$                        | 0.0094      | 0.0050     | 0.0048      |
| $RSD$                       | 1.7         | 1.9        | 1.6         |
| Precision 100% (mg/mL)      |             |            |             |
| $X$                         | 0.971       | 0.495      | 0.612       |
| $SD$                        | 0.0088      | 0.0105     | 0.0058      |
| $RSD$                       | 0.9         | 2.1        | 0.9         |
| Precision 150% (mg/mL)      |             |            |             |
| $X$                         | 1.564       | 0.757      | 0.913       |
| $SD$                        | 0.0270      | 0.0033     | 0.0067      |
| $RSD$                       | 1.7         | 0.4        | 0.7         |
| Recovery 80% (%)            |             |            |             |
| $X$                         | 96.80       | 98.08      | 100.79      |
| $SD$                        | 0.367       | 1.226      | 0.808       |
| $RSD$                       | 0.4         | 1.2        | 0.8         |
| Recovery 100% (%)           |             |            |             |
| $X$                         | 100.75      | 101.12     | 97.88       |
| $SD$                        | 1.280       | 1.798      | 0.559       |
| $RSD$                       | 1.3         | 1.8        | 0.6         |
| Recovery 120% (%)           |             |            |             |
| $X$                         | 98.44       | 97.54      | 98.94       |
| $SD$                        | 0.723       | 0.747      | 0.706       |
| $RSD$                       | 0.7         | 0.8        | 0.7         |

| Rs | HCT : ROS | ROS : CAN |
|----|-----------|-----------|
| 1.80 | 2.50     |

| $\alpha$ | HCT : ROS | ROS : CAN |
|-----------|-----------|-----------|
| 1.62      | 1.82      |

RF - retention factor, $\cdot$ mean value, $SD$ - standard deviation, $RSD$ - relative standard deviation, Rs - resolution factor, $\cdot$ - separation factor.

---

**Determination of components in the model mixture**

The usefulness of the method was assessed by determining the content of tested substances in mixtures resulting from the appropriate solutions prepared from pharmaceutical preparations. 2 µL of standard solutions and the model mixture were applied to TLC plates. Developed and dried chromatograms were subjected to densitometric measurements at the previously given wavelengths. Identification of the determined components was made by comparing the values of $R_f$ coefficients and absorption spectra for the tested model mixtures and standard solutions. To calculate the content of active
substances in the model mixture, the peak areas registered for the tested solutions and the corresponding standard solutions were compared.

RESULTS AND DISCUSSION

The development of the concept of polytablets and research on their application in the therapy and prevention of diseases related to the cardiovascular system, along with the development of technological methods to obtain an effective and safe form of the drug, leads to the need to search for new, simple, cheap, and effective methods of analysis of multi-component drugs.

In accordance with the assumption adopted for the purpose of the work, a new chromatographic and densitometric procedure was developed, allowing for the simultaneous identification and quantification of active substances in a potential ternary poly-tablet composed of CAN, HCT, and ROS. After analyzing the absorption spectra of the tested drugs registered directly from the chromatograms in the range from 200 to 400 nm (Fig. 2), it was found that due to the overlap of absorption maxima for individual components, it is difficult to use the spectrophotometric method to determine these substances in a mixture (12). These interferences mean that the determination of the analytical wavelength for individual components in their mixture does not guarantee satisfactory quantitative results using spectrophotometric or spectrofluorimetric methods.

The selection of a suitable mobile phase was preceded by a literature review and was based on a series of tests that took into account the different qualitative and quantitative composition of solvents. The suitability of the chloroform: methanol: 95.5% acetic acid mixture (9 : 2 : 0.1 V/V) was checked. The use of this phase gave poor resolution and an asymmetrical peak of CAN. In the chloroform: ethyl acetate: 95.5% acetic acid : water (4 : 4 : 4 : 1 V/V) mixture, proper separation of HCT and ROS peaks was not achieved, RF values were very close to each other, which did not guarantee adequate accuracy and precision of determinations. Only peaks from the analyzed components appear on the recorded densitograms. RF values were comparable and were respectively 0.66 ± 0.013 for CAN, 0.41 ± 0.009 for HCT, and 0.53 ± 0.015 for ROS, which gives the

---

Table 2: Linear and quadratic equation of tested substances.

| Substances | Linear equation (p) | Quadratic equation (p) | R² | Mandel's test (p) | Shapiro-Wilk test (p) | Durbin-Watson test (p) | Lagrange's test (p) | Bartlett test (p) |
|------------|---------------------|------------------------|----|------------------|----------------------|----------------------|---------------------|------------------|
| CAN        | P = 4869.1 m + 803.4 (0.000) | P = -934.0 m² + 6612.4 m + 292.7 (0.000) | 0.9987* | 136.53 (0.000) | 0.907* (0.056) | 1.366* | 0.473 (0.508)* | 1.768 (0.184)* |
| HCT        | P = 6109.0 m + 530.0 (0.000) | P = -1168.2 m² + 7464.1 m + 266.7 (0.000) | 0.9990* | 21.11 (0.002) | 0.921* (0.370) | 1.242* | 0.818 (0.366)* | 1.686 (0.682)* |
| ROS        | P = 472.14 m + 264.8 (0.000) | P = -736.8 m² + 5638.3 m + 85.7 (0.000) | 0.9985* | 33.07 (0.000) | 0.978* (0.908) | 1.561* | - | 0.126* (0.723) |

* - for quadratic equation, P - peak surface area; m - mass (g spot-1); R² - coefficient of determination; (p) - p significance.
basis for using the developed procedure in the quantitative analysis. It can therefore be assumed that the method is specific for analyte components, which allows obtaining reliable results (Fig. 3).

The developed method has been fully validated in accordance with the guidelines of the International Conference on Harmonization. In the validation process, linearity, accuracy, precision, the limit of detection LOD, and limit of quantification LOQ were determined. The method is characterized by a high sensitivity; LOD was 0.056 mg/spot for CAN, 0.043 mg/spot for HCT and 0.049 mg/spot for ROS; LOQ was: 0.169 mg/spot, 0.130 mg/spot and 0.150 mg/spot, respectively. Recovery of the determined components was in the range from 96.80% to 101.75%. The results of the determination of individual components are characterized by high precision, RSD was in a narrow range from 0.43% to 2.12%. The determined validation parameters are presented in Table 1.

The linearity of the method was checked in a wide concentration range: from 0.048 to 1.824 mg/spot for CAN, 0.043 mg/spot for HCT and 0.049 mg/spot for ROS; LOQ was: 0.169 mg/spot, 0.130 mg/spot and 0.150 mg/spot, respectively. Recovery of the determined components was in the range from 96.80% to 101.75%. The results of the determination of individual components are characterized by high precision, RSD was in a narrow range from 0.43% to 2.12%. The determined validation parameters are presented in Table 1.

The efficiency of the estimation of calibration models was checked by conducting appropriate statistical tests. Based on Mandel’s test results (p < 0.05 for all tested substances) a quadratic fit was selected. The normal distribution of residuals was confirmed in all cases by the Shapiro-Wilk test. The Durbin-Watson test results indicate no significant autocorrelation of random components only in the case of ROS. The Lagrange test was performed for HCT and CAN, which showed no significant autocorrelation. The Bartlett test confirmed the homogeneity of the variance of random components in the proposed models (p > 0.05). The results of statistical tests and equations are presented in Table 2.

The proposed method was successfully used for the analysis of Carzap® HCT and Suvardio tablet extract solution – model mixture (Table 3). The chromatograms obtained during the analysis, on which no additional peaks from the auxiliary components of the tested drug form were observed and recovery values indicate that the excipients have no effect on the determination results. This allows us to state that with minimal effort and the elimination of complicated activities related to the appropriate sample preparation, results with a satisfactory level of precision and accuracy have been achieved.

CONCLUSIONS

This study presents a new method for the simultaneous determination of candesartan, hydrochlorothiazide, and rosuvastatin in a model mixture of a potential ternary pharmaceutical preparation using TLC – densitometric method. The developed procedure has been validated in accordance with the ICH requirements for chromatographic methods. The TLC method is fast and requires no complicated pre-treatment or tedious extraction procedure, and the obtained results are characterized by high accuracy and precision. The choice of the components of the model mixture was not accidental because in hypertension polytherapy you can find more and more often research on the effectiveness of using various combinations of substances from the group of angiotensin II receptor blockers, diuretics, and HMG-CoA reductase blockers. Due to such a direction in therapy, the pharmaceutical industry is introducing new complex preparations to the market, which in clinical trials gave satisfactory results and underwent the registration procedure. However, the goal of analysts is to develop new, simple, cheap, and easily available methods that could be used for routine analysis of tested drugs in quality control laboratories.

Conflicts of interest

The authors have declared no conflicts of interest.

Table 3. Determination results of active substances in a studied model mixture (n = 5).

| Model mixture | CAN (mg/mL) | HCT (mg/mL) | ROS (mg/mL) |
|---------------|-------------|-------------|-------------|
| Determined content | X = 0.808 | X = 0.625 | X = 0.517 |
| SD = 0.0161 | SD = 0.0040 | SD = 0.0067 | RSD = 2.0% | RSD = 0.6% | RSD = 1.3% |
| Stated content | 0.800 | 0.625 | 0.500 |

X - mean value, SD - standard deviation, RSD - relative standard deviation.
REFERENCES

1. http://www.clinicaltrials.gov/show/NCT00468923 (accessed on 3. 10. 2019).
2. Moisei A., Totan M., Gligor F.G., Craciun I., Todoran N., et al.: Farmacia 64, 612 (2016).
3. Balamuralikrishna K., Syamasundar B.: Pharma. Chem. 2, 231 (2010).
4. Harikrishnan N., Vijaya Var Prasad M., Mohamied A.S., Prabahar K.K.: Int. J. Pharm. Sci. Res. 7, 75 (2016).
5. Erk N.: J. Liq. Chromatogr. Related Technol. 26, 2581 (2003).
6. Youssef R.M., Maher H.M., Hassan E.M., El-Kimary E.I., Barary M.A.: Int. J. Appl. Chem. 6, 233 (2010).
7. Stolarczyk M., Maúlanka A., Krzek J.: J. Liq. Chromatogr. Related Technol. 31, 1892 (2008).
8. Mehta B.H., Morge S.B.: J. Planar. Chromatogr. Mod. TLC 21, 173 (2008).
9. Kull M.E.A., Naguib I.A.: Curr. Pharm. Anal. 13, 188 (2017).
10. Routhu K.C., Annapurna M.M.: IJPT. 8, 17528 (2016).
11. Erk N.: Pharmazie 58, 796 (2003).
12. Belal T.S., Daabeeb H.G., Abdel-Khalek M.M., Mahrous M.S., Khamis M.M.: J. Pharm. Anal 3, 118 (2013).
13. Ali H., Zafar F., Shah S.N., Mallick N., Naveed S., et al.: Lat. Am. J. Pharm. 35, 1710 (2016).
14. Chen D., Lin Z., Wang Q., Su K., Mo J., et al.: Lat. Am. J. Pharm. 35, 2314 (2016).
15. Swathi S., Kumar H.T., Rao P.K., Rao S.Y.: Int. J. Pharm. Pharm. Sci. 7, 209 (2015).
16. Purkar A.J., Balap A.R., Sathiyanarayanan L., Mahadik K.R.: Int. J. Pharm. Pharm. Sci. 6, 704 (2014).
17. Ramadan A.A., Al-Akra H., Maktabi M.: Int. J. Pharm. Pharm. Sci. 6, 180 (2014).
18. Ramadan A.A., Mandil H., Alshelhawi N.: Int. J. Pharm. Pharm. Sci. 6, 579 (2014).
19. Gupta A., Mishra P., Shah K.: E-J. Chem. 6, 89 (2009).
20. Ramadan A.A., Mandil H., Ghazal N.: Int. J. Pharm. Pharm. Sci. 7, 389 (2015).
21. Ramadan A.A., Mandil H., Ghazal N.: Int. J. Pharm. Pharm. Sci. 7, 300 (2015).
22. Silva T.A., Zanin H., Vicentini F.C., Corat E.J., Fatibello-Filho O.: Sensor. Acutat. B-Chem. 218, 51 (2015).
23. Silva T.A., Pereira G.F., Fatibello-Filho O., Eguiluz K.I.B., Salazar-Banda G.R.: Diam. Relat. Mater. 58, 103 (2015).
24. Karadas-Bakirhan N., Gumustas M., Uslu B., Ozkan S.A.: Ionics 22, 277 (2016).
25. Yusuf S., Phil D., Lonn E., Pais P., Bosch J., et al.: N. Engl. J. Med. 374, 2032 (2016).
26. Park D.B., Jang K., Lee J.W., Park C.W., Lee B.H., et al.: Int. J. Clin. Pharmacol. Ther. 55, 286 (2017).
27. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf; (accessed on 20.10.2019).
28. Polish Pharmacopoeia, XIth edition, The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Warszawa 2018.